latest news releases from the newsroom
Metso Paper's Gaspesia Project into Conclusion
HELSINKI, Finland, Nov. 4, 2005 (PRIMEZONE) -- Metso Paper received in 2002 an order for a rebuild of an extensive printing and writing paper line from Papiers Gaspesia in Chandler, Quebec, Canada. The rebuild was expected to be completed in mid 2004. The project was, however, stopped early 2004 due to problems in financing. Consequently Metso Paper's accounts receivable were written off by EUR 15 million in total. The write down was included in the 2004 financial result.
Enea Sells Remaining own Shares
TABY, Sweden, Nov. 4, 2005 (PRIMEZONE) -- As per November 3, 2005, Enea has sold the remaining 59 880 own shares at an average share price of SEK 4.65 in accordance with a mandate from the Annual General Meeting of May 18, 2005. The shareholding originates from a previous incentive program.
Murray, Frank & Sailer LLP
Investor Notice: Murray, Frank & Sailer LLP Has Filed a Shareholder Class Action Against Barrier Therapeutics, Inc. -- BTRX
NEW YORK, Nov. 3, 2005 (PRIMEZONE) -- Murray, Frank & Sailer LLP has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of purchasers of Barrier Therapeutics, Inc. ("Barrier") (Nasdaq:BTRX)(Berlin:BTRX)(Berlin:BXE) common stock during the period between April 29, 2004 and June 29, 2005 (the "Class Period"). Shareholders who purchased Barrier stock in the Initial Public Offering ("IPO") on April 29, 2004 and/or in its Secondary Offering on February 9, 2005 are also included in this class action. Murray, Frank & Sailer LLP is seeking to pursue remedies under the Securities Exchange Act of 1934 and the Securities Act of 1933 against defendants Barrier Therapeutics, Inc., Geert Cauwenbergh, Anne M. Vanlent and Charles T. Nomides.
ViroPharma Announces Additional Investment for Vancocin Supply
EXTON, Pa., Nov. 3, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the amendment of its manufacturing agreement with Eli Lilly and Company (Lilly) (NYSE:LLY) in order to increase Lilly's supply of Vancocin(r) to ViroPharma over and above the supply necessary to meet ViroPharma's expectations for product demand. ViroPharma will pay Lilly an additional amount of up to $4.5 million in addition to the original contract price through early 2006. This investment is representative of ViroPharma's effort to anticipate the potential for increased demand for the product, should the incidence and severity of Clostridium difficile infection continue to increase at a higher than expected rate. Vancocin is indicated for the treatment of antibiotic-associated pseudomembranous colitis caused by C. difficile.
Wireless Xcessories Group
Wireless Xcessories Group Reports Third Quarter Results
HUNTINGDON VALLEY, Pa., Nov. 3, 2005 (PRIMEZONE) -- Wireless Xcessories Group, Inc. (AMEX: XWG), a nationwide distributor of over 4,000 accessories for cellular phones and other wireless devices, announced today results for the third quarter ended September 30, 2005. The company reported revenue of $5,293,000, an increase of 29.9% compared to $4,075,000 for the same period in fiscal 2004. Wireless Xcessories had 2005 third quarter pre-tax net income of $439,000, an increase of 69.5% versus 2004 third quarter pre-tax net income of $259,000. The company had net income of $ 321,000, or $0.07 per basic and diluted share, an increase of 23.9 % compared to net income of $ 259,000, or $0.06 per basic and diluted share in the same period for 2004. The company accrued taxes in the 2005 third fiscal quarter, of $118,000 compared to no taxes in the 2004 third fiscal quarter. The Company utilized its available Federal and State net operating tax loss carry forward benefit in 2004 to offset its tax expense. The Federal portion of the net operating loss carry forward was fully used up in the first six months of 2005 and accordingly, the Company began accruing taxes in the third quarter of 2005.